Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan:112:106625.
doi: 10.1016/j.cct.2021.106625. Epub 2021 Nov 15.

Implementation of platform trials in the COVID-19 pandemic: A rapid review

Alyssa M Vanderbeek  1 , Judith M Bliss  1 , Zhulin Yin  1 , Christina Yap  2
Affiliations
Review

Implementation of platform trials in the COVID-19 pandemic: A rapid review

Alyssa M Vanderbeek et al. Contemp Clin Trials. 2022 Jan.

Abstract

Motivation: Platform designs - master protocols that allow for new treatment arms to be added over time - have gained considerable attention in recent years. Between 2001 and 2019, 16 platform trials were initiated globally. The COVID-19 pandemic seems to have provided a new motivation for these designs. We conducted a rapid review to quantify and describe platform trials used in COVID-19.

Methods: We cross-referenced PubMed, ClinicalTrials.gov, and the Cytel COVID-19 Clinical Trials Tracker to identify platform trials, defined by their stated ability to add future arms.

Results: We identified 58 COVID-19 platform trials globally registered between January 2020 and May 2021. According to trial registries, 16 trials have added new therapies (median 3, IQR 4) and 11 have dropped arms (median 3, IQR 2.5). About 50% of trials publicly share their protocol, and 31 trials (53%) intend to share trial data. Forty-nine trials (84%) explicitly report adaptive features, and 21 trials (36%) state Bayesian methods.

Conclusions: During the pandemic, there has been a surge in the number of platform trials compared to historical use. While transparency in statistical methods and clarity of data sharing policies needs improvement, platform trials appear particularly well-suited for rapid evidence generation. Trials secured funding quickly and many succeeded in adding new therapies in a short time period, thus demonstrating the potential for these trial designs to be implemented beyond the pandemic. The evidence gathered here may provide ample insight to further inform operational, statistical, and regulatory aspects of future platform trial conduct.

Keywords: Adaptive design; COVID-19; Drug development; Master protocols; Platform trials.

PubMed Disclaimer

Conflict of interest statement

CY serves as a consultant/independent contractor with Faron Pharmaceuticals, and as an honorarium recipient with Celgene. JMB reports grants and non-financial support from AstraZeneca, Merck Sharp & Dohme, Puma Biotechnology, Clovis Oncology, Pfizer, Janssen-Cilag, Novartis, Roche, and Eli Lilly.

Figures

Fig. 1
Fig. 1
PRISMA flowchart for combined search and selection at two time points. We searched ClinicalTrials.gov for master protocols in any indication (October 21, 2020) and COVID-19 (June 22, 2021). We searched PubMed for master protocols in any indication (October 21, 2020 and June 22, 2020). The full Cytel COVID-19 Clinical Trials Tracker dataset was retrieved on November 4th for COVID-19-specific trials of any design. A trial was labeled as platform if it is stated on the trial registration webpage, in a publication, or in the full study protocol that the trial allows for the addition of future arms [3]. A trial was labeled as “potential” platform if the listed sources contained language that suggested but could not confirm the flexibility to add arms, or the trial self-identifies as platform but has no further information.
Fig. 2
Fig. 2
COVID-19 platform trial initiation from January 2020 through May 2021. Trial status is shown as classified in ClinicalTrials.gov. A completed trial is one where the final data collection for the primary endpoint has been done for all enrolled participants. None of the four completed trials (ACTT-1, ACTT-2, ACTT-3, and NCT04328961) showed evidence of having added any treatment arms.
See this image and copyright information in PMC

References

    1. Nasrallah A.A., Farran S.H., Nasrallah Z.A., Chahrour M.A., Salhab H.A., Fares M.Y., Khachfe H.H., Akl E.A. A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis. J. Clin. Epidemiol. 2020;125:170–178. doi: 10.1016/j.jclinepi.2020.06.005. - DOI - PMC - PubMed
    1. National Library of Medicine ClinicalTrials.gov COVID-19 Studies. 2021. https://clinicaltrials.gov/ct2/results?cond=COVID-19&age_v=&gndr=&type=I... (n.d.) (accessed July 19, 2021)
    1. Woodcock J., LaVange L.M. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med. 2017;377:62–70. doi: 10.1056/NEJMra1510062. - DOI - PubMed
    1. Saville B.R., Berry S.M. Efficiencies of platform clinical trials: a vision of the future. Clin. Trials. 2016;13:358–366. doi: 10.1177/1740774515626362. - DOI - PubMed
    1. Dimairo M., Pallmann P., Wason J., Todd S., Jaki T., Julious S.A., Mander A.P., Weir C.J., Koenig F., Walton M.K., Nicholl J.P., Coates E., Biggs K., Hamasaki T., Proschan M.A., Scott J.A., Ando Y., Hind D., Altman D.G., ACE Consensus Group The Adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ. 2020;369:m115. doi: 10.1136/bmj.m115. - DOI - PMC - PubMed